Medtronic Evolut TAVR system show durable clinical outcomes

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement, TAVR, system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in the JACC, the flagship journal of the American College of Cardiology. The Evolut Low Risk Trial was a randomized, multicenter, international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients. Patients with severe aortic stenosis who were treated with either Evolut TAVR or surgery showed comparable rates of all-cause mortality or disabling stroke at 5 years and surgery. Additional findings at five years include: Numerically lower rate of cardiovascular mortality; Significantly larger effective orifice areas and lower mean gradients in the TAVR vs. surgical arms